Welcome to our dedicated page for JOHNSON & JOHNSON SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (JNJ), reported transactions dated 08/15/2025. He exercised 16,820 employee stock options at an exercise price of $101.87 and simultaneously sold 16,820 common shares at a weighted-average sale price of $176.9067 (trades ranged $176.87–$177.015). After these transactions his direct beneficial ownership is reported as 14,000 shares. He also holds 68,835 shares indirectly via a spousal lifetime access trust (SLAT) and 2,145 shares indirectly through the Johnson & Johnson 401(k) stock fund. The form was signed by an attorney-in-fact on 08/18/2025.
Form 144 notice for Johnson & Johnson (JNJ): The filing reports a proposed sale of 16,820 shares of common stock through Fidelity Brokerage Services LLC on the NYSE with an approximate sale date of 08/15/2025. The filing lists an aggregate market value of $2,975,571.23 for the shares and shows 2,408,338,872 shares outstanding. The securities were acquired under options granted on 02/08/2016, the purchaser is listed as the issuer, and the indicated form of payment is cash. The filer certifies they have no undisclosed material adverse information.